The aim of our study was to assess the effects of lacidipine, a long-acting calcium
antagonist, on 24-hour average blood pressure, blood pressure variability, and baroreflex …

A sensitive and reproducible method for the determination of lacidipine, a new potent
antihypertensive dihydropyridine, is reported. The method involves solid-phase extraction …

Several types of calcium antagonists (CA)(verapamil, diltiazem, nifedipine and related
drugs) may be used as antihypertensives. In practice, the dihydropyridines (nifedipine and …

The second half of the 20th century has seen a constant de-crease in cardiovascular
mortality in the Western industrialised nations [1]. This decrease has occurred concomitantly …

Multiple studies have demonstrated dihydropyridine calcium‐channel blocker (CCB) therapy
to be appropriate for the treatment of hypertension, as is reflected in treatment guidelines …

Lipophilic dihydropyridines have many theoretical and practical clinical advantages owing to
their long permanence at the cell membrane. They have a greater chance of smoothly and …

Lercanidipine is a new highly lipophylic dihydropyrdine derivative of the third generation
with equal efficacy but an improved tolerability profile. Comparative therapeutic trials have …

Among the various drugs currently available for the treatment of systemic hypertension,
calcium antagonists continue to receive much attention because of their established efficacy …

To determine whether the antihypertensive effectiveness of lercanidipine was independent
of the different cardiovascular risk levels. Patients with treated or untreated mild‐to …

Lacidipine, a third generation dihydropyridine calciumantagonist, has demonstrated
pronounced anti-atherosclerotic activity in preclinical studies. The drug can act at several …